Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shereen Oon

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Rheumatology (Oxford, England)|March 18, 2022
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosusSharzad Emamikia, Shereen Oon, Alvaro Gomez, et al.
JCI Insight|October 5, 2016
A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosusShereen Oon, Huy Huynh, Tsin Yee Tai, et al.
Iscience|July 17, 2023
CSL362 potently and specifically depletes pDCs <i>in</i><i>vitro</i> and ablates SLE-immune complex-induced IFN responsesKatherine A Monaghan, Alberta Hoi, Cristina Gamell, et al.
The Lancet. Rheumatology|August 29, 2024
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trialsIoannis Parodis, Julius Lindblom, Roger A Levy, et al.
Seminars in Arthritis and Rheumatism|February 21, 2017
Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity studyVera Golder, Molla Huq, Kate Franklyn, et al.
Arthritis Research & Therapy|May 12, 2026
Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort studyRangi Kandane-Rathnayake, Rachel Koelmeyer, Shereen Oon, et al.
Arthritis Care & Research|October 18, 2024
Impact of Season, Environmental Temperature, and Humidity on Raynaud Phenomenon in an Australian Systemic Sclerosis CohortLaura Taylor, Dylan Hansen, Kathleen Morrisroe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 25, 2014
Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-α productionYifan Zhan, Emma M Carrington, Hyun-Ja Ko, et al.
RMD Open|July 15, 2026
Multicentre international audit of IMACS malignancy screening guidelines in idiopathic inflammatory myopathies: insights from the myositis audit and research collaborative groupJessica Day, Lekshmi Minikumari Rahulan, Samuel Katsuyuki Shinjo, et al.
Lupus Science & Medicine|January 20, 2025
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosusRangi Kandane-Rathnayake, Dominique Milea, Worawit Louthrenoo, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Rheumatology (Oxford, England)|March 18, 2022
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosusSharzad Emamikia, Shereen Oon, Alvaro Gomez, et al.
JCI Insight|October 5, 2016
A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosusShereen Oon, Huy Huynh, Tsin Yee Tai, et al.
Iscience|July 17, 2023
CSL362 potently and specifically depletes pDCs <i>in</i><i>vitro</i> and ablates SLE-immune complex-induced IFN responsesKatherine A Monaghan, Alberta Hoi, Cristina Gamell, et al.
The Lancet. Rheumatology|August 29, 2024
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trialsIoannis Parodis, Julius Lindblom, Roger A Levy, et al.
Seminars in Arthritis and Rheumatism|February 21, 2017
Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity studyVera Golder, Molla Huq, Kate Franklyn, et al.
Arthritis Research & Therapy|May 12, 2026
Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort studyRangi Kandane-Rathnayake, Rachel Koelmeyer, Shereen Oon, et al.
Arthritis Care & Research|October 18, 2024
Impact of Season, Environmental Temperature, and Humidity on Raynaud Phenomenon in an Australian Systemic Sclerosis CohortLaura Taylor, Dylan Hansen, Kathleen Morrisroe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 25, 2014
Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-α productionYifan Zhan, Emma M Carrington, Hyun-Ja Ko, et al.
RMD Open|July 15, 2026
Multicentre international audit of IMACS malignancy screening guidelines in idiopathic inflammatory myopathies: insights from the myositis audit and research collaborative groupJessica Day, Lekshmi Minikumari Rahulan, Samuel Katsuyuki Shinjo, et al.
Lupus Science & Medicine|January 20, 2025
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosusRangi Kandane-Rathnayake, Dominique Milea, Worawit Louthrenoo, et al.
Pageof 6